

## Harbour BioMed and Evinova China announce strategic collaboration to accelerate Al-enabled drug development

10 November 2025 | News

## To enhance the efficiency of innovative biologics development



Harbour BioMed, a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Evinova, a global health-tech company accelerating the delivery of better health outcomes by propelling the life sciences sector forward in digital health, have announced a strategic collaboration in artificial intelligence (AI).

Under the terms of the collaboration, Harbour BioMed and Evinova China will jointly apply AI and digital technologies to enhance the efficiency of innovative biologics development. Building on their own strengths, the two companies aim to build an open ecosystem for AI-driven drug R&D.

Dr Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, stated, "Harbour BioMed has built a robust and differentiated product pipeline based on our industry-leading Harbour Mice<sup>®</sup> technology platform. Through this collaboration, we look forward to applying AI to improving clinical study efficiency and accelerating the delivery of innovative therapies to patients around the world."

Nate Zhang, General Manager of Evinova China, stated, "Evinova leverages the digital transformation insights of top global pharmaceutical companies to design our Al-powered clinical development solutions and digital strategy consulting services, so that we can accelerate the delivery of better health outcomes. To realize our mission, Evinova China needs to partner with innovative companies like Harbour BioMed, which are rooted in China while harboring global ambitions. Together, through our world-class Al technology platforms and deep therapeutic expertise, we can help take China-originated breakthrough assets from the laboratory to the world."